Diala Ezzeddine

- Brenus is a clinical stage biotech company. - Lead program is a novel colorectal cancer (CRC) immuno-oncology therapeutic, STC-1010, currently in Ph1. - Proprietary platform for a novel modality of in vivo cancer therapeutics.

Molecular Dynamics + AI for predictive protein degradation and induced proximity drug development

- Advising biotech companies in BD and fundraising. - Various fractional C-level executive roles in several biotech companies since 2020.

- Epigene is a pioneer in AI-powered cancer omic data curation for enabling AI-mediated precision medicine. - Advising the CEO on corporate strategy and BD

- Company developing novel molecular glues for induced proximity other than degradation using a platform jointly conceived with Prof. Stuart Schreiber, Prof. Ben Cravatt, and several other academic luminaries. - Negotiated Magnet's first multi-year pharma parntership in Oncology with Lilly - up to $40M in upfront + near-term payments; $1.2B deal value. - Supported CEO in raising Series A extension of $25M with new investors Lilly and Taiho Ventures joining original investors ARCH Venture Partners and Newpath Partners. - Advised CEO and leadership team on pivoting to the Immuno/Inflammation (I&I) space.

- Founded Xios as an X-Chem spinout in oral small molecules for immuno-oncology; raised $8M Series A led by Sutter Hill Ventures. - Deployed DEL screening and PROTAC technology to discover and develop novel immuno-oncology therapeutics. - Assembled an immuno-oncology and protein degradation SAB of top notch academics (Dana-Farber, Harvard Medical School) and industry experts. - Jointly with X-Chem, established in 2021 a discovery partnership with Servier for neurological disorders (terms undisclosed).

- Led BD and Alliance Management teams in executing additional pharma deals and expanding existing deals. - Played a key role in creating several X-Chem spinouts.

- Founding CBO, instrumental in establishing X-Chem as the leading DNA-Encoded Library technology company. - Built innovative business model and established drug discovery partnerships with multiple top tier pharma companies, including Roche, AZ, Bayer, Pfizer, Sanofi, J&J, EMD Serono, Astellas, and others. - Supported CEO in raising $15M in equity funding in 2010 and selling X-Chem at multiplied valuation in 2014. - Built a team of experienced BD executives. - Established a best practice Alliance Management team.

- Leading company in aptamer therapeutics. - Executed a major partnership with GSK in 2009 ($27M upfront, >$1B deal value).

- Company established to develop orthopedic applications for a novel hydrogel material mimicking the biomechanics of natural hydrogels present in humans. - Hydrogel technology was licensed to Zimmer Holdings, Inc. (now Zimmer Biomet) for use in hip and knee replacement devices.

Boston, MA

Boston, MA

Beirut, Lebanon

Verneuil-sur-Avre, France

Beirut, Lebanon